AI assistant
AMICUS THERAPEUTICS, INC. — Director's Dealing 2017
Oct 16, 2017
31523_dirs_2017-10-16_cd9451d6-9359-434a-9a05-e6250a95dd42.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: AMICUS THERAPEUTICS INC (FOLD)
CIK: 0001178879
Period of Report: 2017-10-12
Reporting Person: Baird William D III (Chief Financial Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2017-10-12 | Common Stock | M | 40000 | $14.2533 | Acquired | 135121 | Direct |
| 2017-10-12 | Common Stock | S | 40000 | $14.2533 | Disposed | 95121 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2017-10-12 | Stock Options (right to buy) | $2.52 | M | 40000 | Disposed | 2023-06-18 | Common Stock (40000) | Direct |
Footnotes
F1: The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 9, 2017.
F2: This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.08 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
F3: This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $14.08 to $14.44. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.